title: Safety profile of capecitabine as maintenance treatment after induction with XELOX or FOLFOX in metastatic colorectal cancer patients.
authors.affiliation: Department of Oncology, Polo Oncologico, Azienda Ospedaliero-Universitaria Pisana, Istituto Toscano Tumori, Pisa Department of Medical Oncology, University of Pisa, Pisa, Italy.
authors.forename: C
authors.initials: C
authors.lastname: Cremolini
authors.affiliation: Department of Oncology, Polo Oncologico, Azienda Ospedaliero-Universitaria Pisana, Istituto Toscano Tumori, Pisa Department of Medical Oncology, University of Pisa, Pisa, Italy.
authors.forename: R
authors.initials: R
authors.lastname: Moretto
authors.affiliation: Department of Oncology, Polo Oncologico, Azienda Ospedaliero-Universitaria Pisana, Istituto Toscano Tumori, Pisa Department of Medical Oncology, University of Pisa, Pisa, Italy.
authors.forename: G
authors.initials: G
authors.lastname: Masi
authors.affiliation: Department of Oncology, Polo Oncologico, Azienda Ospedaliero-Universitaria Pisana, Istituto Toscano Tumori, Pisa Department of Medical Oncology, University of Pisa, Pisa, Italy alfredo.falcone@med.unipi.it.
authors.forename: A
authors.initials: A
authors.lastname: Falcone
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols; D000069287:Capecitabine; D015179:Colorectal Neoplasms; D003841:Deoxycytidine / Q000031:analogs & derivatives; D005472:Fluorouracil / Q000031:analogs & derivatives; D006801:Humans; D002955:Leucovorin; D009944:Organoplatinum Compounds; D010071:Oxaloacetates
chemical_list: D009944:Organoplatinum Compounds; D010071:Oxaloacetates; D003841:Deoxycytidine; D000069287:Capecitabine; D002955:Leucovorin; D005472:Fluorouracil